Sanofi (SNY)
USD 47.01
(-3.94%)
USD 47.01
(-3.94%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 46.03 Billion EUR | -5.11% |
| 2022 | 45.38 Billion EUR | 15.86% |
| 2021 | 39.17 Billion EUR | 4.83% |
| 2020 | 37.36 Billion EUR | -0.7% |
| 2019 | 37.63 Billion EUR | 5.48% |
| 2018 | 35.67 Billion EUR | -1.5% |
| 2017 | 36.22 Billion EUR | 4.4% |
| 2016 | 34.69 Billion EUR | -0.47% |
| 2015 | 34.86 Billion EUR | 8.94% |
| 2014 | 31.99 Billion EUR | 2.26% |
| 2013 | 31.29 Billion EUR | -12.98% |
| 2012 | 35.95 Billion EUR | 2.56% |
| 2011 | 35.05 Billion EUR | 3.0% |
| 2010 | 34.03 Billion EUR | 10.69% |
| 2009 | 30.74 Billion EUR | 6.7% |
| 2008 | 28.81 Billion EUR | -1.34% |
| 2007 | 29.2 Billion EUR | -0.96% |
| 2006 | 29.48 Billion EUR | 3.5% |
| 2005 | 28.49 Billion EUR | 81.23% |
| 2004 | 15.72 Billion EUR | 95.69% |
| 2003 | 8.03 Billion EUR | 7.77% |
| 2002 | 7.45 Billion EUR | 14.91% |
| 2001 | 6.48 Billion EUR | 8.8% |
| 2000 | 5.96 Billion EUR | 11.46% |
| 1999 | 5.35 Billion EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 11.11 Billion EUR | -51.41% |
| 2024 Q2 | 21.2 Billion EUR | 2.36% |
| 2023 Q4 | 22.88 Billion EUR | 80.21% |
| 2023 Q2 | 10.68 Billion EUR | -1.67% |
| 2023 Q3 | 12.69 Billion EUR | 18.87% |
| 2023 Q1 | 10.86 Billion EUR | -5.18% |
| 2023 FY | 43.07 Billion EUR | -5.11% |
| 2022 FY | 45.38 Billion EUR | 15.86% |
| 2022 Q3 | 13.13 Billion EUR | 22.3% |
| 2022 Q1 | 10.05 Billion EUR | -3.48% |
| 2022 Q2 | 10.74 Billion EUR | 6.85% |
| 2022 Q4 | 11.45 Billion EUR | -12.8% |
| 2021 Q2 | 9.04 Billion EUR | 1.79% |
| 2021 Q3 | 10.82 Billion EUR | 19.72% |
| 2021 Q4 | 10.41 Billion EUR | -3.82% |
| 2021 FY | 39.17 Billion EUR | 4.83% |
| 2021 Q1 | 8.88 Billion EUR | -8.73% |
| 2020 Q4 | 9.73 Billion EUR | -1.45% |
| 2020 Q1 | 9.31 Billion EUR | -7.0% |
| 2020 FY | 37.36 Billion EUR | -0.7% |
| 2020 Q3 | 9.87 Billion EUR | 17.08% |
| 2020 Q2 | 8.43 Billion EUR | -9.42% |
| 2019 Q3 | 9.92 Billion EUR | 10.48% |
| 2019 Q2 | 8.98 Billion EUR | 3.06% |
| 2019 Q1 | 8.71 Billion EUR | -6.57% |
| 2019 Q4 | 10.01 Billion EUR | 0.97% |
| 2019 FY | 37.63 Billion EUR | 5.48% |
| 2018 Q3 | 9.74 Billion EUR | 14.89% |
| 2018 Q4 | 9.32 Billion EUR | -4.29% |
| 2018 FY | 35.67 Billion EUR | -1.5% |
| 2018 Q1 | 8.12 Billion EUR | -9.52% |
| 2018 Q2 | 8.48 Billion EUR | 4.37% |
| 2017 FY | 36.22 Billion EUR | 4.4% |
| 2017 Q3 | 9.39 Billion EUR | 5.15% |
| 2017 Q2 | 8.93 Billion EUR | 0.4% |
| 2017 Q1 | 8.89 Billion EUR | -3.05% |
| 2017 Q4 | 8.98 Billion EUR | -4.39% |
| 2016 FY | 34.69 Billion EUR | -0.47% |
| 2016 Q1 | 7.92 Billion EUR | 16.08% |
| 2016 Q4 | 9.17 Billion EUR | -1.27% |
| 2016 Q3 | 9.29 Billion EUR | 11.88% |
| 2016 Q2 | 8.3 Billion EUR | 4.79% |
| 2015 Q1 | 8.22 Billion EUR | -10.36% |
| 2015 Q3 | 9.68 Billion EUR | 10.48% |
| 2015 Q2 | 8.76 Billion EUR | 6.59% |
| 2015 Q4 | 6.83 Billion EUR | -29.44% |
| 2015 FY | 34.86 Billion EUR | 8.94% |
| 2014 Q4 | 9.17 Billion EUR | 3.41% |
| 2014 FY | 31.99 Billion EUR | 2.26% |
| 2014 Q3 | 8.86 Billion EUR | 8.86% |
| 2014 Q2 | 8.14 Billion EUR | 2.79% |
| 2014 Q1 | 7.92 Billion EUR | -7.26% |
| 2013 FY | 31.29 Billion EUR | -12.98% |
| 2013 Q4 | 8.54 Billion EUR | 0.32% |
| 2013 Q3 | 8.51 Billion EUR | 5.34% |
| 2013 Q2 | 8.08 Billion EUR | -0.87% |
| 2013 Q1 | 8.15 Billion EUR | -5.84% |
| 2012 Q2 | 9.11 Billion EUR | 2.01% |
| 2012 Q4 | 8.66 Billion EUR | -6.24% |
| 2012 Q1 | 8.93 Billion EUR | 0.16% |
| 2012 Q3 | 9.24 Billion EUR | 1.35% |
| 2012 FY | 35.95 Billion EUR | 2.56% |
| 2011 Q2 | 8.77 Billion EUR | 7.07% |
| 2011 Q1 | 8.19 Billion EUR | 4.89% |
| 2011 Q3 | 9.17 Billion EUR | 4.57% |
| 2011 Q4 | 8.92 Billion EUR | -2.71% |
| 2011 FY | 35.05 Billion EUR | 3.0% |
| 2010 Q3 | 8.25 Billion EUR | 0.83% |
| 2010 Q1 | 7.77 Billion EUR | 0.6% |
| 2010 FY | 34.03 Billion EUR | 10.69% |
| 2010 Q4 | 7.81 Billion EUR | -5.44% |
| 2010 Q2 | 8.19 Billion EUR | 5.35% |
| 2009 Q1 | 7.45 Billion EUR | -0.07% |
| 2009 Q2 | 7.79 Billion EUR | 4.64% |
| 2009 Q3 | 7.77 Billion EUR | -0.32% |
| 2009 FY | 30.74 Billion EUR | 6.7% |
| 2009 Q4 | 7.72 Billion EUR | -0.55% |
| 2008 Q2 | 7.1 Billion EUR | 0.14% |
| 2008 Q3 | 7.16 Billion EUR | 0.85% |
| 2008 Q1 | 7.09 Billion EUR | -13.1% |
| 2008 FY | 28.81 Billion EUR | -1.34% |
| 2008 Q4 | 7.45 Billion EUR | 4.06% |
| 2007 Q2 | 7.33 Billion EUR | 3.9% |
| 2007 Q1 | 7.05 Billion EUR | -4.47% |
| 2007 Q3 | 6.96 Billion EUR | -4.92% |
| 2007 Q4 | 8.16 Billion EUR | 17.12% |
| 2007 FY | 29.2 Billion EUR | -0.96% |
| 2006 Q4 | 7.38 Billion EUR | 0.42% |
| 2006 Q2 | 7.44 Billion EUR | 1.69% |
| 2006 FY | 29.48 Billion EUR | 3.5% |
| 2006 Q3 | 7.35 Billion EUR | -1.19% |
| 2006 Q1 | 7.32 Billion EUR | -0.32% |
| 2005 Q4 | 7.34 Billion EUR | -2.21% |
| 2005 Q3 | 7.5 Billion EUR | 10.24% |
| 2005 Q1 | 6.65 Billion EUR | 25.0% |
| 2005 Q2 | 6.81 Billion EUR | 2.33% |
| 2005 FY | 28.49 Billion EUR | 81.23% |
| 2004 Q3 | 5.33 Billion EUR | 126.42% |
| 2004 Q4 | 5.32 Billion EUR | -0.17% |
| 2004 FY | 15.72 Billion EUR | 95.69% |
| 2004 Q2 | 2.35 Billion EUR | 5.79% |
| 2004 Q1 | 2.22 Billion EUR | 25.71% |
| 2003 FY | 8.03 Billion EUR | 7.77% |
| 2003 Q2 | 1.94 Billion EUR | 0.1% |
| 2003 Q1 | 1.94 Billion EUR | 3.09% |
| 2003 Q4 | 1.77 Billion EUR | -26.71% |
| 2003 Q3 | 2.41 Billion EUR | 24.12% |
| 2002 Q3 | 1.87 Billion EUR | 1.87% |
| 2002 Q4 | 1.88 Billion EUR | 0.86% |
| 2002 FY | 7.45 Billion EUR | 14.91% |
| 2002 Q2 | 1.83 Billion EUR | 0.0% |
| 2001 FY | 6.48 Billion EUR | 8.8% |
| 2000 FY | 5.96 Billion EUR | 11.46% |
| 1999 FY | 5.35 Billion EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Amgen Inc. | 28.19 Billion USD | -63.295% |
| AstraZeneca PLC | 45.81 Billion USD | -0.485% |
| Biogen Inc. | 9.83 Billion USD | -368.024% |
| Gilead Sciences, Inc. | 27.11 Billion USD | -69.763% |
| MIRA Pharmaceuticals, Inc. | - USD | -Infinity% |
| Scilex Holding Company | 46.74 Million USD | -98381.056% |
| Scilex Holding Company | 46.74 Million USD | -98381.056% |